Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,518 questions in 135 reviews · Infectious Diseases
current versionsNo studies 135 · 8.9%Ungraded 150 · 9.9%Very low 350 · 23.1%Low 420 · 27.7%Moderate 321 · 21.1%High 142 · 9.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Oral ivermectin 200 μg/kg (1 to 3 doses) vs topical ivermectin 1% lotion/solution (1 to 3 applications) Complete clearance ‐ week 4 · people with scabies, 5 to 80 years of ageLocation: Egypt, India Ivermectin and permethrin for treating scabies (2018) · Cochrane | RR 0.99 [0.95, 1.03] | 2 studies · 272 participants | Moderate |
Oral ivermectin 200 μg/kg (1 to 3 doses) vs topical ivermectin 1% lotion/solution (1 to 3 applications) Number of participants with ≥ 1 AE ‐ week 4 · people with scabies, 5 to 80 years of ageLocation: Egypt, India Ivermectin and permethrin for treating scabies (2018) · Cochrane | RR 5.05 [0.25, 103.87] | 1 study · 201 participants | Very low |
Oral ivermectin 200 μg/kg (1 to 3 doses) vs topical ivermectin 1% lotion/solution (1 to 3 applications) Withdrawal due to AE ‐ week 4 · people with scabies, 5 to 80 years of ageLocation: Egypt, India Ivermectin and permethrin for treating scabies (2018) · Cochrane | no estimate extracted | 1 study · 62 participants | Moderate |
Oral ivermectin 200 μg/kg (1 to 3 doses) vs topical permethrin 5% cream (1 to 3 applications) Complete clearance ‐ week 2 · people with scabies, 2 to 80 years of ageLocation: India, Pakistan Ivermectin and permethrin for treating scabies (2018) · Cochrane | RR 0.91 [0.76, 1.08] | 5 studies · 459 participants | Low |
Topical ivermectin 1% lotion (1 to 3 applications) vs topical permethrin 5% cream (1 to 3 applications) Complete clearance ‐ week 4 · people with scabies, 5 to 80 years of ageLocation: India Ivermectin and permethrin for treating scabies (2018) · Cochrane | RR 1.02 [0.96, 1.08] | 1 study · 210 participants | Moderate |
Topical ivermectin 1% lotion (1 to 3 applications) vs topical permethrin 5% cream (1 to 3 applications) Number of participants with ≥ 1 AE ‐ week 4 · people with scabies, 5 to 80 years of ageLocation: India Ivermectin and permethrin for treating scabies (2018) · Cochrane | RR 0.33 [0.01, 7.93] | 1 study · 200 participants | Very low |
Oral ivermectin 200 μg/kg (1 dose) vs oral ivermectin 200 μg/kg (2 doses) Complete clearance ‐ week 4 · people with scabies, over 5 years of ageLocation: India Ivermectin and permethrin for treating scabies (2018) · Cochrane | RR 0.97 [0.83, 1.14] | 1 study · 80 participants | High |
Oral ivermectin 200 μg/kg (1 dose) vs oral ivermectin 200 μg/kg (2 doses) 1Sharma 2011. · people with scabies, over 5 years of ageLocation: India Ivermectin and permethrin for treating scabies (2018) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Oral ivermectin 200 μg/kg (1 to 3 doses) vs topical permethrin 5% cream (1 to 3 applications) Complete clearance ‐ week 4 ‐ IVER 1 dose versus PER 1 application · people with scabies, 2 to 80 years of ageLocation: India, Pakistan Ivermectin and permethrin for treating scabies (2018) · Cochrane | RR 1 [0.86, 1.16] | 1 study · 80 participants | High |
Oral ivermectin 200 μg/kg (1 to 3 doses) vs topical permethrin 5% cream (1 to 3 applications) Complete clearance ‐ week 4 ‐ IVER 1 to 3 doses versus PER 1 to 3 applications · people with scabies, 2 to 80 years of ageLocation: India, Pakistan Ivermectin and permethrin for treating scabies (2018) · Cochrane | RR 0.92 [0.82, 1.03] | 5 studies · 581 participants | Low |
Oral ivermectin 200 μg/kg (1 to 3 doses) vs topical permethrin 5% cream (1 to 3 applications) Complete clearance ‐ week 4 ‐ IVER 2 doses versus PER 1 application · people with scabies, 2 to 80 years of ageLocation: India, Pakistan Ivermectin and permethrin for treating scabies (2018) · Cochrane | RR 0.97 [0.83, 1.14] | 1 study · 80 participants | High |
Oral ivermectin 200 μg/kg (1 to 3 doses) vs topical permethrin 5% cream (1 to 3 applications) Number of participants with ≥ 1 AE ‐ week 2 · people with scabies, 2 to 80 years of ageLocation: India, Pakistan Ivermectin and permethrin for treating scabies (2018) · Cochrane | no estimate extracted | 1 study · 55 participants | Moderate |
Oral ivermectin 200 μg/kg (1 to 3 doses) vs topical permethrin 5% cream (1 to 3 applications) Number of participants with ≥ 1 AE ‐ week 4 · people with scabies, 2 to 80 years of ageLocation: India, Pakistan Ivermectin and permethrin for treating scabies (2018) · Cochrane | RR 1.3 [0.35, 4.83] | 4 studies · 502 participants | Low |
Oral ivermectin 200 μg/kg (1 to 3 doses) vs topical permethrin 5% cream (1 to 3 applications) Withdrawal due to AE ‐ week 4 · people with scabies, 2 to 80 years of ageLocation: India, Pakistan Ivermectin and permethrin for treating scabies (2018) · Cochrane | no estimate extracted | 3 studies · 305 participants | Moderate |
Oral ivermectin 200 μg/kg (1 to 2 doses) vs topical permethrin 5% lotion (1 to 5 applications) Complete clearance ‐ week 1 ‐ IVER 1 dose versus PER 1 application · people with scabies, 5 to 60 years of ageLocation: Egypt, Pakistan Ivermectin and permethrin for treating scabies (2018) · Cochrane | RR 0.93 [0.74, 1.17] | 1 study · 120 participants | Moderate |
Intervention NR Death from all causes · HIV‐negative people with tuberculous pericarditis Interventions for treating tuberculous pericarditis (2017) · Cochrane | RR 0.8 [0.59, 1.09] | 4 studies · 660 participants | Low |
Intervention NR Cancer · HIV‐positive people with tuberculous pericarditis. Most patients (80%) not on antiretroviral drugs Interventions for treating tuberculous pericarditis (2017) · Cochrane | RR 1.62 [0.27, 9.77] | 1 study · 502 participants | Very low |
Intervention NR Death from pericarditis · HIV‐negative people with tuberculous pericarditis Interventions for treating tuberculous pericarditis (2017) · Cochrane | RR 0.39 [0.19, 0.8] | 4 studies · 660 participants | Moderate |
Intervention NR Constrictive pericarditis · HIV‐negative people with tuberculous pericarditis Interventions for treating tuberculous pericarditis (2017) · Cochrane | RR 0.72 [0.34, 1.55] | 2 studies · 281 participants | Very low |
Intervention NR Repeat pericardiocentesis · HIV‐negative people with tuberculous pericarditis Interventions for treating tuberculous pericarditis (2017) · Cochrane | RR 0.85 [0.7, 1.04] | 2 studies · 492 participants | Low |
Intervention NR Cancer · HIV‐negative people with tuberculous pericarditis Interventions for treating tuberculous pericarditis (2017) · Cochrane | RR 0.85 [0.05, 13.8] | 1 study · 256 participants | Very low |
Intervention NR Death from all causes · HIV‐positive people with tuberculous pericarditis. Most patients (80%) not on antiretroviral drugs Interventions for treating tuberculous pericarditis (2017) · Cochrane | RR 0.91 [0.34, 2.42] | 3 studies · 575 participants | Very low |
Intervention NR Death from pericarditis · HIV‐positive people with tuberculous pericarditis. Most patients (80%) not on antiretroviral drugs Interventions for treating tuberculous pericarditis (2017) · Cochrane | RR 1.07 [0.46, 2.54] | 2 studies · 517 participants | Very low |
Intervention NR Constrictive pericarditis · HIV‐positive people with tuberculous pericarditis. Most patients (80%) not on antiretroviral drugs Interventions for treating tuberculous pericarditis (2017) · Cochrane | RR 0.55 [0.26, 1.16] | 3 studies · 575 participants | Low |
Intervention NR Repeat pericardiocentesis · HIV‐positive people with tuberculous pericarditis. Most patients (80%) not on antiretroviral drugs Interventions for treating tuberculous pericarditis (2017) · Cochrane | RR 1.02 [0.89, 1.18] | 2 studies · 517 participants | Low |
Intervention NR Residual pleural fluid on chest X‐ray at 8 weeks · adults and adolescents with pleural TB Corticosteroids for tuberculous pleurisy (2017) · Cochrane | RR 0.54 [0.37, 0.78] | 2 studies · 237 participants | Low |
Intervention NR Residual pleural fluid on chest X‐ray at 24 weeks · adults and adolescents with pleural TB Corticosteroids for tuberculous pleurisy (2017) · Cochrane | RR 0.35 [0.18, 0.66] | 2 studies · 237 participants | Low |
Intervention NR Pleural changes at the end of · adults and adolescents with pleural TB Corticosteroids for tuberculous pleurisy (2017) · Cochrane | RR 0.72 [0.57, 0.92] | 5 studies · 393 participants | Low |
Intervention NR Long‐term functional respiratory impairment (> 6 months) · adults and adolescents with pleural TB Corticosteroids for tuberculous pleurisy (2017) · Cochrane | no estimate extracted | 2 studies · 187 participants | Very low |
Intervention NR Adverse events leading to treatment discontinuation ( · adults and adolescents with pleural TB Corticosteroids for tuberculous pleurisy (2017) · Cochrane | RR 2.78 [1.11, 6.94] | 6 studies · 590 participants | Low |
Intervention NR HIV‐related infections (cryptococcal meningitis) · adults and adolescents with pleural TB Corticosteroids for tuberculous pleurisy (2017) · Cochrane | RR 0.59 [0.15, 2.42] | 1 study · 103 participants | Very low |
Intervention NR HIV‐related cancer (Kaposi's sarcoma) · adults and adolescents with pleural TB Corticosteroids for tuberculous pleurisy (2017) · Cochrane | RR 12.87 [0.73, 225.4] | 1 study · 103 participants | Very low |
Intervention NR HIV infection status of the child · HIV‐positive women during pregnancy and immediate postpartum period Vitamin A supplements for reducing mother‐to‐child HIV transmission (2017) · Cochrane | RR 1.07 [0.91, 1.26] | 5 studies · 4428 participants | Moderate |
Intervention NR Mean birthweight · HIV‐positive women during pregnancy and immediate postpartum period Vitamin A supplements for reducing mother‐to‐child HIV transmission (2017) · Cochrane | MD 34.12 | 3 studies · 2181 participants | Low |
Intervention NR Low birthweight · HIV‐positive women during pregnancy and immediate postpartum period Vitamin A supplements for reducing mother‐to‐child HIV transmission (2017) · Cochrane | RR 0.78 [0.63, 0.97] | 3 studies · 1819 participants | Moderate |
Intervention NR Child death by two years of age · HIV‐positive women during pregnancy and immediate postpartum period Vitamin A supplements for reducing mother‐to‐child HIV transmission (2017) · Cochrane | RR 1.06 [0.92, 1.22] | 3 studies · 3883 participants | Low |
Intervention NR Preterm delivery · HIV‐positive women during pregnancy and immediate postpartum period Vitamin A supplements for reducing mother‐to‐child HIV transmission (2017) · Cochrane | RR 0.84 [0.52, 1.37] | 2 studies · 1577 participants | Very low |
Intervention NR Stillbirth · HIV‐positive women during pregnancy and immediate postpartum period Vitamin A supplements for reducing mother‐to‐child HIV transmission (2017) · Cochrane | RR 1.13 [0.72, 1.77] | 3 studies · 2335 participants | Very low |
Intervention NR Maternal death · HIV‐positive women during pregnancy and immediate postpartum period Vitamin A supplements for reducing mother‐to‐child HIV transmission (2017) · Cochrane | RR 0.71 [0.35, 1.43] | 2 studies · 1267 participants | Very low |
Multiple micronutrients vs placebo Mortality · adults with HIV infection (with and without concurrent tuberculosis, with and without ART) Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | RR 0.91 [0.72, 1.15] | 7 studies · 2897 participants | Low |
Vitamin A vs placebo Change in vitamin A concentrations (µmol/L) · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | no estimate extracted | 3 studies · 495 participants | Low |
Vitamin D vs placebo Mortality · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | RR 1.15 [0.65, 2.02] | 1 study · 131 participants | Very low |
Vitamin D vs placebo Morbidity · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Vitamin D vs placebo CD4 cell count (cells/mm³) · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | no estimate extracted | 4 studies · 288 participants | Low |
Vitamin D vs placebo Viral load (log10copies/mL) · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | no estimate extracted | 1 study · 28 participants | Very low |
Vitamin D vs placebo Change in 25(OH) vitamin D concentrations (ng/mL) · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | no estimate extracted | 4 studies · 299 participants | Moderate |
Zinc vs placebo Mortality · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | RR 1.24 [0.53, 2.86] | 3 studies · 433 participants | Very low |
Zinc vs placebo Rate of diarrhoea · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | OR 0.4 [0.18, 0.87] | 1 study · 231 participants | Very low |
Zinc vs placebo Change in CD4 cell count (cells/mm³) · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | no estimate extracted | 4 studies · 431 participants | Low |
Zinc vs placebo Change in viral load (log10copies/mL) · adults with HIV infection Micronutrient supplementation in adults with HIV infection (2017) · Cochrane | no estimate extracted | 3 studies · 400 participants | Low |